OURA

It started in Oulu, Finland in 2013 — which is about as far from Silicon Valley as you can get without falling into the Arctic Ocean. Petri Lahtela, Hannu Harri, and Kari Kivelä were researchers and engineers obsessed with one question: what if you could measure the body's real recovery state, not just steps or heart rate, but deep physiological signals that actually tell you whether you're ready to perform or about to crash?

They believed the finger was the best place to measure this. The arteries in your finger sit close to the surface, making optical heart rate and blood oxygen readings more accurate than from the wrist.

That's not a marketing claim — it's anatomy. They spent years building the sensor array small enough to fit inside a ring while still capturing infrared LEDs, accelerometers, gyroscopes, and temperature sensors simultaneously.

The company's first Kickstarter in 2015 raised around $648,000 — modest, but enough to prove that people would pay for a ring that tracked sleep rather than notifications. The early product was chunky and clearly prototype-grade.

But the data it produced was genuinely good, which is not something most wearables can claim. Researchers at places like UCSF started using it in studies.

The NBA partnered with Oura during the COVID bubble season in 2020 to monitor player health — 1,200 rings, real epidemiological use. That partnership changed everything.

Suddenly Oura wasn't a Finnish startup. It was the ring the NBA trusted when the stakes were actual human health.

Oura sells hardware and charges a subscription. That's the model.

You pay around $299–$549 for the ring depending on the style, and then $5.99 a month for the Oura app that actually interprets all that raw sensor data into something actionable.

The hardware margin is decent but not spectacular — manufacturing a precision sensor ring at scale isn't cheap. The real economics are in the subscription.

Once someone is wearing the ring and tracking their sleep, readiness, and activity every day, they almost never cancel. The churn rate on health wearables that people actually use daily is extremely low.

Oura is betting that once you're hooked on your readiness score, $6 a month is nothing.

Oura also sells through retail — Best Buy, Amazon, its own website — which keeps customer acquisition costs manageable compared to pure DTC plays. And it has a B2B angle that most people miss: corporate wellness programs and research partnerships.

When companies pay to give employees Oura rings as part of health benefit packages, or universities use Oura data in clinical trials, those are high-value bulk deals that improve margins and generate legitimacy simultaneously.

The subscription pivot happened in 2021 and annoyed some early adopters who expected the app to stay free forever. But it also turned Oura from a hardware company with one-time revenue into something investors could model as a recurring revenue business.

That reframe is worth hundreds of millions of dollars in valuation.

The Oura Ring is the entire product. There is no Oura Watch, no Oura earbuds, no Oura scale.

They make one thing. That focus is either brilliant discipline or a vulnerability depending on who you ask.

The ring itself is a sensors-in-a-ring engineering achievement. Packed inside a titanium band that weighs about 4–6 grams are infrared and red LED sensors, a photodetector for pulse oximetry, a 3D accelerometer, a gyroscope, and a temperature sensor accurate to 0.1 degrees Celsius.

Battery lasts 4–7 days. It's water resistant to 100 meters.

You can wear it lifting weights, swimming, and sleeping — which is the point.

The Oura app translates all of that raw physiological data into three daily scores: Readiness, Sleep, and Activity. Readiness is the flagship — it's a 0–100 score that synthesises your resting heart rate, heart rate variability, body temperature, sleep quality, and activity levels to tell you how recovered you actually are.

The insight that your HRV dropped 15 points overnight and your temperature is slightly elevated before you even feel sick is genuinely useful, not just impressive-sounding.

Generation 4, launched in 2024, added improved optical sensors, a slimmer profile, and the ability to detect cardiovascular health markers with more precision. Oura also added a women's health feature that predicts and tracks menstrual cycles using temperature patterns — and clinical studies showed it can detect early pregnancy.

That feature alone opened a meaningful new user segment.

The NBA bubble was the unlock nobody planned for. When the NBA restarted its 2019–20 season inside a COVID bubble in Orlando, they needed a way to monitor player health in real time.

They chose Oura. Twelve hundred rings.

Every player, coach, and staff member wearing one. The data was used to flag early COVID symptoms before PCR tests even turned positive.

It worked. ESPN covered it.

Sports journalists who had never heard of a Finnish health startup were suddenly writing about readiness scores.

That single partnership did more for Oura's credibility than any marketing campaign could have. It wasn't a sponsorship — it was operational use in a high-stakes real-world scenario.

The signal it sent to the market was clear: this is the ring serious institutions trust with serious decisions.

From there, the flywheel was influencer-driven in the most authentic way possible. Athletes, biohackers, physicians, and longevity-obsessed executives started wearing it and talking about it.

Peter Attia has mentioned it. Andrew Huberman has discussed it.

The Joe Rogan audience found it. These aren't paid placements — they're people who are genuinely obsessed with optimising their biology and found a tool they actually believe in.

Oura also made a smart style bet. They made the ring look good.

Polished titanium, minimalist, available in multiple finishes. It doesn't scream 'I am tracking my data.' It looks like jewelry.

That matters enormously to a segment of the market that refused to wear a Fitbit or Apple Watch because of how it looked at a dinner table.

The competition is coming and it is coming from people with unlimited budgets. Samsung launched the Galaxy Ring in 2024.

Apple has ring-shaped patents circulating and a smartwatch ecosystem that already has 100 million users who might never need a separate ring. Google owns Fitbit.

These are not scrappy competitors — they are trillion-dollar companies that can outspend Oura in marketing, undercut it on price, and bundle ring functionality into existing device ecosystems for free.

Oura's moat is data accuracy and trust built over a decade of research. That's real.

But it's not invincible. If Samsung ships a Galaxy Ring with genuinely comparable sensor accuracy — and early reviews suggest it's close — the average consumer is going to buy the ring that works with their existing Samsung phone, not the Finnish one that costs more and requires a separate subscription.

There's also a regulatory risk that almost nobody talks about. Oura has been careful to market its metrics as 'wellness' rather than 'medical' to avoid FDA scrutiny.

But as the company pushes further into detecting illness, flagging pregnancy complications, or monitoring chronic disease — all of which are active research areas — the line between wellness device and medical device gets blurry. Medical device regulation is expensive, slow, and could significantly constrain how Oura markets its most compelling features.

And then there's the subscription churn problem that comes with any recurring revenue model. Oura raised prices and added a mandatory subscription in 2021.

Some users left. The question is whether the product is good enough to keep new users paying $72 a year forever — or whether, like most fitness apps, usage drops off after six months.

Oura's investor list reads like a who's who of people who believe in longevity, biohacking, and the idea that wearable health data is going to be worth a lot more than fitness tracking.

Warrant Group and Temasek, the Singaporean sovereign wealth fund, led the Series C in 2021 — a $100 million round that valued the company at $2.55 billion. Temasek backing is significant not just for the capital but for the signal: a government-backed institutional investor doesn't put money into a gadget company, they put it into a health data platform they believe has durable long-term value.

SoftBank Vision Fund also participated, which brings the usual caveats — SoftBank has funded some spectacular flameouts — but also the distribution network and operational support that comes with the Vision Fund ecosystem. Earlier backers include Forerunner Ventures and Square, which point to Oura's consumer brand ambitions, as well as WS Investment Company.

Perhaps most interestingly, Jennifer Doudna — the Nobel Prize-winning biochemist who co-invented CRISPR — is an advisor. That's not a capital relationship, but it speaks to the scientific credibility Oura has built within the research and medical community.

When serious scientists are willing to attach their names to your product, it means the data is real.